Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Jonathan Brammer
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07356245CT.gov Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma | — | Recruiting | — | — | — |
NCT01712659CT.gov Ruxolitinib for Adult T-Cell Leukemia | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Adult T-Cell Leukemia/Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ruxolitinib (this asset) | Jonathan Brammer | P2 | B · 59 |
| Cyclophosphamide | John Reneau | P4 | BBB |
| Dexasone | The First Affiliated Hospital of Soochow University | P2 | BBB |
| Fludarabine | John Reneau | P2 | BBB |
| Etoposide | National Cancer Institute (NCI) | P2 | BBB |
| Lenalidomide | National Cancer Institute (NCI) | P2 | BBB |
| Rituximab | Northwestern University | P2 | BBB |
| Mogamulizumab | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Cediranib | Morphotek | P2 | BB |
+42 more in the Adult T-Cell Leukemia/Lymphoma cohort
Other indications for Ruxolitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Primary Myelofibrosis | — | P4 | BBB · 73 |
| Disease Related To Hematopoietic Stem Cell Transplant | — | P4 | BB · 70 |
| Graft Versus Host Disease | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ruxolitinib in Adult T-Cell Leukemia/Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ruxolitinib-adult-t-cell-leukemialymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →